Abemaciclib mesylate (LY2835219)

Catalog No.S7158

For research use only.

Abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.

Abemaciclib mesylate (LY2835219) Chemical Structure

CAS No. 1231930-82-7

Selleck's Abemaciclib mesylate (LY2835219) has been cited by 64 publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Other CDK Products

Biological Activity

Description Abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Targets
CDK4 [1]
(Cell-free assay)
CDK6 [1]
(Cell-free assay)
2 nM 10 nM
In vitro

LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human COLO205 cells M2jQeGZ2dmO2aX;uJIF{e2G7 MmfoNlQhcA>? M{DDcWlvcGmkaYTpc44hd2ZiQ1TLOE83KGmwIHj1cYFvKEORTF:yNFUh[2WubIOgZZN{\XO|ZXSgZZMhdWG6aX31cUBk\WyuIHP5Z4xmKGG{cnXzeEBifCCJMTDwbIF{\SCjZoTldkAzPCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXN? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNUW3NUc,OjZzMUW1O|E9N2F-
human COLO205 cells M4rCfGZ2dmO2aX;uJIF{e2G7 M2LU[FI1KGh? MlzwTY5pcWKrdHnvckBw\iCFRFu0M|YhcW5iaIXtZY4hS0:OT{KwOUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGLiJJBpd3OyaH;yfYxifGmxbjDh[pRmeiB{NDDodpMh[nlicILvdIllcXWvIHnv[Ill\SC|dHHpcolv\y2kYYPl[EBt[XOncj3zZ4FvdmmwZzDmcJVwemW|Y3XuZ4UhdWmlcn;wcIF1\SCleYTvcYV1emmlIHHuZYx6e2m| MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNUW3NUc,OjZzMUW1O|E9N2F-
insect cells  MYnGeY5kfGmxbjDhd5NigQ>? MmrJOVAhdWmwcx?= NV7pUYk2UW6qaXLpeIlwdiCxZjDoeY1idiCFRFu0M4N6[2yrbjDENUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbI9zgWyjdHnvckBw\iCFVGLGJIFnfGW{IEWwJI1qdnNiYomgcYlkem:ybHH0[UB{[2mwdHnscIF1cW:wIHPveY51\XJuIFnDOVA:OiCwTR?= NXvmcJNORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVU2PzFpPkK2NVE2PTdzPD;hQi=>
insect cells  M3ridmZ2dmO2aX;uJIF{e2G7 NV\ZbI5IPTBibXnudy=> NHzHfItEd22yZYTpeIl3\SCrbnjpZol1cW:wIH;mJIh2dWGwIFPET|Qw[3mlbHnuJGQyKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMh[XO|ZYPz[YQh[XNicHjvd5Bpd3K7bHH0bY9vKG:oIFPUVmYh[W[2ZYKgOVAhdWmwczDifUBOcWOqYXXsbZMuVWWwdHXuJJBtd3RiYX7hcJl{cXNiaX6gdJJme2WwY3Wgc4YhSVSSLDDLbV0xNjZibl2= Mn;VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUW1O|EoRjJ4MUG1OVcyRC:jPh?=
HCT116 MWTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M{LyRlczKGi{cx?= MXTJR|UxKD1iMD61OEDPxE1? NFroXm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEG2OVM1OSd-M{CxOlU{PDF:L3G+
MCF7 NXfYZ45{SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NIGwToY4OiCqcoO= MWfJR|UxKD1iMD63NUDPxE1? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF4NUO0NUc,OzBzNkWzOFE9N2F-
PANC1 NHLLZ3lCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NXzkZo5OPzJiaILz M3fTWmlEPTBiPTC1Mlk1KM7:TR?= NHH6PWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEG2OVM1OSd-M{CxOlU{PDF:L3G+
Sf9 M4G3VmZ2dmO2aX;uJIF{e2G7 NVjqNWszUW6qaXLpeIlwdiCxZjDDSGsyN0O7Y3zpckBDKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcnHsJIlv\mWldHXkJIlve2WldDDT[lkh[2WubIOgeZNqdmdiaHnzeI9v\SCKMTDhd{B{fWK|dILheIUhcW5icILld4Vv[2Vib3[gX4didW2jLUOzVH1CXFBuIFnDOVAhRSByLkO3NUDPxE1w MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd2MUi1N{c,OjZ5NEG4OVM9N2F-
Sf9 NHXqO2VHfW6ldHnvckBie3OjeR?= MlHXPVAhdWmwcx?= NUC0V2dwUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGdUXC22YXfn[YQhS0SNNDCoOEB1dyB|MEOgdoV{cWS3ZYOpM4N6[2yrbjDENUApPCC2bzCyPVUhemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDz[lkh[2WubIOgeZNqdmdiQz30[ZJucW6jbDDy[ZRqdm:kbHHzeI9u[SCocnHncYVvfCCjczDzeYJ{fHKjdHWgZYZ1\XJiOUCgcYlveyCkeTDb[4FudWFvM{PQYWFVWCCkYYPl[EBucWO{b3LleIEhe2OrboTpcIxifGmxbjDjc5VvfGmwLDDLbUA:KDBwMECyJO69VS5? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN|Y9N2F-
Sf9 MYPGeY5kfGmxbjDhd5NigQ>? Mm\rPVAhdWmwcx?= NH72Z3pKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIZ2dGxibHXu[5RpKGi3bXHuJG4ufGW{bXnuZYwhT1OWLYTh[4dm\CCFRFu2JEgyKHSxIEOyOkBz\XOrZIXld{kw[3mlbHnuJGQyKCh2IITvJFI6PSC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJJNnQSClZXzsd{B2e2mwZzDDMZRmem2rbnHsJJJmfGmwb3LsZZN1d22jIH\yZYdu\W62IHHzJJN2[nO2cnH0[UBi\nSncjC5NEBucW6|IHL5JHto[W2vYT2zN3BeSVSSIHLhd4VlKG2rY4LvZoV1[SC|Y3nueIltdGFuIFvpJF0hOC5yMTFOwG0v MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN|Y9N2F-
Sf21 Mlv2SpVv[3Srb36gZZN{[Xl? MmDZTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDDMZRmem2rbnHsJGhqezZvdHHn[4VlKEOGS{evZ5lkdGmwIFivUk11\XKvaX7hcEBIW1RvdHHn[4VlKE2DVEGg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|IHnu[oVkfGWmIGPmNlEhcW6|ZXP0JINmdGy|IIXzbY5oKGOma{egd5Vje3S{YYTlJJBmeHSrZHWsJGtqKD1iMz65NUDPxE1w NV[3b3ZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexO|ExOzZpPkK3NVcyODN4PD;hQi=>
COLO205 M4rRV2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 M2q0bFk3KGi{cx?= NUOwXZlTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDU2xQOjB3IHPlcIx{KGGodHXyJFk3KGi{czDifUBES0tvODDhd5NigSxiSVO1NEA:KDBwNE[g{txONg>? NXWybVVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwO|QzPTRpPkK5NFc1OjV2PD;hQi=>
U87MG NGHQ[JBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M4fUfFczKGi{cx?= MmrWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCXOEfNS{Bk\WyuczDh[pRmeiB5MjDodpMh[nliRFHQTUB{fGGrbnnu[{Bj[XOnZDDhd5NigSxiSVO1NEA:KDBwMES4NUDPxE1w NIHMdlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK0O|g2Pyd-MkmyOFc5PTd:L3G+
Sf9 NH22VWNHfW6ldHnvckBie3OjeR?= Ml[wTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCQLYTldo1qdmGuIFfTWE11[WepZXSgR2RMPCBqU{SgeI8hTTNyMzDy[ZNq\HWnczmvR5lkdGmwIFSxJEhSPCC2bzDJNlk2KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gd4Y6KGOnbHzzJJV{cW6pIGLiJJBzd3SnaX6gLFc4OyC2bzC5NlghemW|aXT1[ZMqKGG|IIP1ZpN1emG2ZTDpckBxemW|ZX7j[UBw\iCdM{PQYU1CXFBiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yCvZYToc4QtKEmFNUCgQUAxNjByMjFOwG0v MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR{OUizNkc,Ojl2Mkm4N|I9N2F-
Sf9 MUnGeY5kfGmxbjDhd5NigQ>? MlnSPVAhdWmwcx?= Ml\1TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDDSGs3KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliaX7z[YN1KGOnbHzzJJV{cW6pIHjpd5RwdmViSEGgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomgRWRRNUeubzDhd5NigSxiSVO1NEA:KDBwMEC3PEDPxE1w NFrJV3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSyPVg{Oid-Mkm0Nlk5OzJ:L3G+
Sf9 MUHGeY5kfGmxbjDhd5NigQ>? M3X1cmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QufGGpZ3XkJGNFUzRiKF2xJJRwKEF|Mk[gdoV{cWS3ZYOpM2N6[2yrbjDENUApWTRidH:gTVI6PSC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJJNnQSClZXzsd{B2e2mwZzDSZkBxem:2ZXnuJEg4PzNidH:gPVI5KHKnc3nkeYV{MSCjczDzeYJ{fHKjdHWgbY4heHKnc3XuZ4Uhd2ZiW{OzVH0uSVSSIHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmdibXX0bI9lNCCLQ{WwJF0hOC5yMTFOwG0v MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR{OUizNkc,Ojl2Mkm4N|I9N2F-
Sf9 MX7GeY5kfGmxbjDhd5NigQ>? MYq5NEBucW6| NFyxdIVKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJGNFUzFxQ4njcIlvKER|IHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkmgbY5{\WO2IHPlcIx{KHW|aX7nJIhqe3SxbnWgTFEhe3Wkc4TyZZRmKGGodHXyJFkxKG2rboOgZpkhSUSSLVfsc{Bie3OjeTygTWM2OCB;IECuNFU3KM7:TT6= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR{OUizNkc,Ojl2Mkm4N|I9N2F-
MDA-MB-231 MmLYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idg>? MXy3NkBpenN? NIi0bllCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KESDUFmgd5RicW6rbnegZoF{\WRiYYPzZZktKEmFNUCgQUAxNjF7MTFOwG0v M136b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEK5PFMzLz5{OUSyPVg{OjxxYU6=
COLO205 NWrYOGM4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbh?= M17JcFk3KGi{cx?= M4XsOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1;MU|IxPSClZXzsd{Bi\nSncjC5OkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFAvOjF5IN88UU4> MlLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NUmyO|QoRjJ7NEW5Nlc1RC:jPh?=
MDA-MB-468 MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFv NG\wUXQ6PiCqcoO= MmfsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuPDZ6IHPlcIx{KGGodHXyJFk3KGi{czDifUBES0t6IHHzd4F6NCCLQ{WwJF0hPC56MEig{txONg>? M1HXcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEW5Nlc1Lz5{OUS1PVI4PDxxYU6=
COLO205 MVTJcohq[mm2aX;uJI9nKEOGS{SgbY4hcHWvYX6= Ml3CNE4yKHSxIEGwJJVO NHLJR5AzPCCqcoO= NFf3dXVKdmirYnn0bY9vKG:oIFPET|QhcW5iaIXtZY4hS0:OT{KwOUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5idH;0ZYwhWmJicILveIVqdiCuZY\lcEBifCByLkGgeI8hOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4T0bY5oKG2ndHjv[C=> M4HIb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEW5Nlc1Lz5{OUS1PVI4PDxxYU6=
COLO205 MUXD[YxtKGO7Y3zlJIF{e2G7 NEmyPXZ2eCC2bzCxNEB2VQ>? NE\XbG8zPCCqcoO= NEX4W4pE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBEV0yRMkC1JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNk9OKHCqYYPlJJVxKHSxIEGwJJVOKGGodHXyJFI1KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJie2WmIF\BR3Mh[W6jbInzbZM> MnSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NUmyO|QoRjJ7NEW5Nlc1RC:jPh?=
Assay
Methods Test Index PMID
Western blot p-Rb(S780) / Rb / p21 ; p-ERK / ERK / p-Akt / Akt / p-mTOR(S2448) / mTOR ; pRb(S795) / E2F1 / Cyclin A2 / Cyclin E2 26909611 27748766
Growth inhibition assay Cell viability 26909611
In vivo LY2835219 saturates BBB efflux with an unbound plasma IC50 of about 95 nM. The percent of dose in brain for LY2835219-MsOH is 0.5–3.9%. In both a subcutaneous and intracranial human glioblastoma model (U87MG), LY2835219-MsOH suppressed tumor growth in a dose-dependent manner both as a single agent, and in combination with temozolomide. [1]

Protocol (from reference)

Solubility (25°C)

In vitro

Water 100 mg/mL
(165.92 mM)
DMSO 83 mg/mL
(137.71 mM)
Ethanol '''24 mg/mL

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.

100mg/mL

Chemical Information

Molecular Weight 602.7
Formula

C27H32F2N8.CH4O3S

CAS No. 1231930-82-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F.CS(=O)(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05169567 Not yet recruiting Drug: Abemaciclib|Drug: Fulvestrant|Drug: Placebo Breast Neoplasm|Neoplasm Metastasis Eli Lilly and Company January 14 2022 Phase 3
NCT04791384 Not yet recruiting Drug: Abemaciclib|Drug: Elacestrant Breast Cancer Criterium Inc. January 1 2022 Phase 1|Phase 2
NCT04967521 Recruiting Drug: Abemaciclib|Drug: Placebo Advanced Dedifferentiated Liposarcoma Sarcoma Alliance for Research through Collaboration|Eli Lilly and Company November 11 2021 Phase 3
NCT04750928 Recruiting Drug: Abemaciclib Neurofibromatosis 1 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) November 29 2021 Phase 1|Phase 2
NCT04941274 Recruiting Drug: Abemaciclib Kaposi Sarcoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) September 29 2021 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Is your product S7158 LY2835219 “mesylate salt form”?

Answer:
Our S7158 LY2835219 is mesylate salt form.

Tags: buy Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219) supplier | purchase Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219) cost | Abemaciclib mesylate (LY2835219) manufacturer | order Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219) distributor